Biogen Inc. (BIIB) Q1 2026 (USD): Adj. EPS 3.57 (exp. 2.99), Revenue 2.5bln (exp. 2.25bln); sees FY Adj. EPS 14.20-15.25 (exp. 15.46, prev. saw 15.25-16.25)
- Updated guidance includes an approximately USD 1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy
Context
Biogen Inc. reported a strong Q1 2026, beating both EPS and revenue expectations significantly. However, their FY guidance was slightly reduced, with IPR&D charges impacting adjusted earnings, which investors may view as a mixed signal regarding future profitability and growth strategies in an already competitive biotech sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#BIOGEN IDEC INC#BIIB.US#FOREX#EQUITIES#METALS#EU SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#DXY#US EQUITIES